ROARABLE
FREE $100K
My Trading Account β†’
β–Ύ
Trading Profile Active
Active Trader
Verified Trader
⚑ My $100K Trading Account β†’ β˜… My Saved Watchlist β†’
🟒 My $100K Account β†’ Today Screener Big Ideas Track Record πŸ’° $100K Arena 🎲 Predictions πŸ›οΈ Insiders 8 Analysts
Stock Ratings / Health Care / CNTB / insiders
HYPD (38) CTOR (34) IBIO (23) GANX (41) ⌘ Pro Terminal β†’

Connect Biopharma Holdings Limited (CNTB) Insider, 13F Hedge Fund & Politician Buy/Sell Thermometer

$0.78 -3.13% NASDAQ β€’ Live Quote vs Prior Daily Close (Synced Snapshot) EXT / AFTER-HRS: $0.77

Connect Biopharma Holdings Limited (CNTB) carries a Roarable Rating of E (Strong Sell) with 26/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.

ROARABLE E β€’ RED ALERT Cap $50.5M
πŸ“€ Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card
⚑ INSTANT AI QUANT PREVIEW β€’ $0 FREE TIER Click Any Pre-Computed AI Quant Specialist Briefing on CNTB Below β€” or Connect Your Own ChatGPT / Claude
πŸ€– Mara Quenwick β€’ AI Quant Lead (Click for Instant Brief) Is CNTB stock a Buy, Hold, or Sell right now according to Roarable's RQD model?
β–Ό

As of 2026-11-03, Connect Biopharma Holdings Limited (NASDAQ: CNTB) is rated E (Strong Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 26/100 at a spot price of $0.78 (-3.13% 1D, market cap $50.5M). Pillar breakdown: Fundamental Cash Engine 7/20, Institutional 13F & Options Flow 3/20, SEC Balance-Sheet Forensics 5/20, FRED Macro Regime Fit 8/20, and Executive Insider Alignment 3/20. Across 1015 tracked Health Care issuers, CNTB ranks #913 in composite RQD confidence.

βœ“ Pre-computed one-to-many AI Quant brief
πŸ€– Ellis Vennor β€’ AI Peer & Flow Quant (Click for Instant Brief) How does CNTB compare to HYPD and CTOR in the Health Care sector?
β–Ό

Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), CNTB carries a Roarable E (26/100 RQD), trailing P/E of N/A, gross margin of β€”, and ROIC of -35.0%. By comparison, HYPD (Hyperion DeFi Inc.) holds a D- grade (38/100 RQD, P/E N/A, ROIC -35.0%, cap $49.7M) and CTOR (Citius Oncology Inc.) posts a E grade (34/100 RQD, P/E N/A, ROIC -35.0%, cap $51.5M). Among the 5-stock peer group, CNTB leads on earnings multiple (N/A) while CNTB leads on capital efficiency (-35.0% ROIC).

βœ“ Pre-computed one-to-many AI Quant brief
πŸ€– Gideon Ashmere β€’ AI SEC 10-K Forensics (Click for Instant Brief) What are the biggest fundamental strengths and SEC risk factors for CNTB?
β–Ό

Per CNTB's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001835268), Connect Biopharma Holdings Limited generated $64.0K in revenue (-99.8% YoY), -$55.5M in net income, and -$51.6M in free cash flow against $56.1M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately. Institutional options positioning shows a 50% call / 50% put premium split.

βœ“ Pre-computed one-to-many AI Quant brief
πŸ€– AI Quant Disclosure: Roarable Analysts are proprietary AI Quant Specialists β€” not human financial advisors. Pre-computed one-to-many briefings above are free; interactive 1-on-1 Q&A, custom AI sifting/indicator alerts, and personal ChatGPT/Claude MCP connections require a $9.95/mo Pro account (currently waitlist-only).
INTERACTIVE SCENARIO DECK:
πŸ›‘οΈ Portfolio Crash X-Ray
EXT / AFTER-HRS: $0.77 (-0.75%)🧬 Dilution Drag (+1.28% YoY Shares)βš™οΈ Cash Engine: 7/20 (D-) β€’ 0% FCF Margin
Verify 90D Bucket Audit β†’
πŸ“Š Historical Track Record Warning: Scores below 50 (26/100 Β· E) historically underperformed SPY in 71% of rolling 90-day windows (-10.5% avg 90D alpha vs SPY β€’ 29.0% hit rate).
Audit Bucket Track Record β†’
RQD QUANT TACHOMETERRED ALERT β€’ E
025507510026
3-of-3 Quant Analysts Bearish Warning
Cash
SEC
Whale

Impersonal quantitative research (0–100 RQD rubric) β€” not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR RQD RADARRw E Β· Rk E
Cash (7)Whales (3)SEC (5)Macro (8)CEO (3)
Each axis scored 0–20
12M PRICE TARGET CONE-14.1% Base Target
$4 Bull$1 Base$1 Bear
πŸ“¬ FREE CNTB RATING-CHANGE & BRIEFING ALERTSManage / Unsubscribe
WHALE OPTIONS SNAPSHOT: β€” (No Active Options Snapshot on file for CNTB)Realized 20D OHLCV Swing Band: Β±12.5%
Deterministic 5-Pillar Attribution (26/100 Composite)
πŸ” WHY CNTB SCORES 26/100 (E) β€” TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag
β–² #1 Bullish Driver: Macro Regime Fit+8/20 pts (31% of score)

FRED Regime Γ— Technicals: 2% of 52W Range β€’ RSI-14 at 33.2 (NEUTRAL RANGE)

β–² #2 Bullish Driver: Cash Engine Quality+7/20 pts (27% of score)

SEC XBRL FY 2025 (10-K): 0% FCF Margin ($0 FCF) & 52% Gross Margin

β–Ό #1 Drag / Risk Factor: Insider Conviction & Share Dilution4/20 pts (-16 pt drag)

Dilution Drag (+1.28% YoY Shares) & executive Form 4 sales trim 16 pts from alignment

πŸ“ˆ PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 β†’ Q2 β†’ Q3 β†’ Current
Q1 (-3Q)
34
Grade E$0.91-1.1% Next Q
Q2 (-2Q)
31
Grade E$0.90-5.6% Next Q
Q3 (-1Q)
29
Grade E$0.85-8.2% Next Q
Current
26
Grade E$0.78-10.5% Hist 90D Ξ±
Trajectory: E (34) β†’ E (26)Full Audit β†’
βš”οΈ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)CONTRARIAN TURNAROUND & SHORT-SQUEEZE DOSSIER

βš”οΈ Adversarial Opposing Case: What Could Spark a CNTB Turnaround Squeeze

Gideon Ashmere Forensic Desk β†’

While CNTB currently carries a cautious 26/100 (E) rating due to Insider Conviction & Share Dilution (4/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.

πŸš€ Contrarian Squeeze Trigger #1

Established market leader in Health Care with deep daily trading liquidity.

πŸš€ Contrarian Squeeze Trigger #2

Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($1.33) and Max Pain ($0.82) forces dealer call-delta covering toward $4.01.

πŸš€ Contrarian Squeeze Trigger #3

Forensic Repair Trigger: Halting share dilution (Dilution Drag (+1.28% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.

🎲 LIVE PREDICTION MARKET ODDS TIED TO $CNTBβ€’ $2.4M Crowd Pool β€’ Kalshi / Polymarket Composite
Contract: β€œCNTB Beats Next Quarter EPS Consensus (Dec 30, 2026) & Holds Above 200D SMA”
YES 26%NO 74%Trade / Inspect Odds β†’
SEC FORM 4 Γ— 13F HEDGE FUNDS Γ— CONGRESSIONAL STOCK ACT

CNTB Smart-Money Thermometer: NET EXECUTIVE TRIMMING / PROFIT-TAKING

Explore All 13F & Congress Whales β†’
β–² Disclosed Buys: 0 ($0)β–Ό Disclosed Sales: 0 ($0)

Wide-Open SEC Form 4, 13F & Congressional Disclosure Ledger (CNTB)

No recent open-market Form 4 cluster sales or emergency dumps flagged on CNTB. Visit the Global 13F & Congressional Whale Ledger for cross-market smart-money filings.

ON-DEMAND RQD QUANT WORKSHOP β€’ SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk

Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring CNTB)

  • βœ“Walkthrough of CNTB's RQD Radar, SEC cash-conversion gap & downside invalidation levels
  • βœ“3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
  • βœ“Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks
RQD INSIDER CLUB WAITLIST$49/YR PLANNED
Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?
Join Founding VIP Waitlist (No Card Required) β†’$100K Arena
CNTB // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: -68.55%πŸ›‘οΈ HOLDING TREND SUPPORT
2026-11-03O $0.83H $0.83L $0.78C $0.78VOL 2.50M
RES: $3.05SUP: $0.59SMA50: $1.33SMA200: $2.19
$3.08$2.45$1.81$1.17$0.53RES $3.05SUP $0.59$0.782026-05-042026-06-172026-08-042026-09-172026-11-03
PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

CNTB Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

πŸ¦‹ CNTB Butterfly Map β†’ + Track CNTB β†’
Share Count & Dilution Monitor

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle
8.0%/yr Implied 5Y Growth

vs. -99.8% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger

No active Ellis Vennor swing setup published on CNTB today. View full Setup Ledger β†’

πŸ¦‹ Documented & Second-Order Butterfly Connections Open Graph β†’

No direct multi-tier Butterfly edges indexed yet for CNTB. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video
🎬 No recent verified company-specific video clip queued for CNTB today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk β†’
DETERMINISTIC MULTI-FACTOR EQUITY AUDIT β€’ SEC EDGAR XBRL Γ— RQD PEER BENCHMARK

πŸ“Š Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (CNTB)

Health Care Rank #913 of 1015 βš”οΈ HYPD vs CNTB Full Matrix β†’

1. Head-to-Head Health Care Peer Comparison (CNTB vs. HYPD, CTOR, IBIO, GANX)

Industry: Biotechnology: Pharmaceutical Preparations (489 Tracked Issuers)

Across 1015 tracked Health Care securities in the Roarable RQD universe, Connect Biopharma Holdings Limited (CNTB) ranks #913 by composite RQD confidence (26/100, grade E) and #743 by equity capitalization ($50.5M). Within this direct 5-issuer industry benchmark cohort, CNTB leads on earnings valuation at N/A trailing P/E, while CNTB leads on capital efficiency and profitability with -35.0% ROIC and β€” gross margin. GANX currently holds the highest overall quantitative score in the immediate peer group at 41/100 (D-) compared with CNTB at 26/100 (E).

Ticker / Company Roarable Grade RQD Score Trailing P/E Gross Margin ROIC 1D Change Market Cap Head-to-Head
CNTB ACTIVE
Connect Biopharma Holdings Limited
E 26/100 β€” β€” -35.0% -3.13% $50.5M Benchmark Subject
HYPD
Hyperion DeFi Inc.
D- 38/100 β€” 62.7% -35.0% -7.76% $49.7M /hypd-vs-cntb β†’
CTOR
Citius Oncology Inc.
E 34/100 β€” β€” -35.0% +7.24% $51.5M /ctor-vs-cntb β†’
IBIO
iBio Inc.
E 23/100 β€” β€” -35.0% +4.06% $49.4M /ibio-vs-cntb β†’
GANX
Gain Therapeutics Inc.
D- 41/100 β€” β€” -35.0% 0.00% $49.3M /ganx-vs-cntb β†’

2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)

SEC EDGAR 10-K β€’ FILED 2025-12-31 β€’ CIK 0001835268 β†—

In its most recent audited fiscal period (FY2025, filed 2025-12-31), Connect Biopharma Holdings Limited (CNTB) reported GAAP revenue of $64.0K (-99.8% vs. FY2024 revenue of $26.0M , and -100.0% cumulative change since FY2023) , GAAP net income of -$55.5M, operating cash flow of -$51.2M, and free cash flow of -$51.6M (-112.0% YoY). On the balance sheet, CNTB closed FY2025 with $56.1M in total assets against $0 in total debt (Altman Z-Score: N/A, Piotroski F-Score: 2/9).

Fiscal Period Filing Date Revenue Net Income Operating Cash Flow Free Cash Flow Total Assets Total Debt
FY2025 (FY) 2025-12-31 $64.0K -$55.5M -$51.2M -$51.6M $56.1M β€”
FY2024 (FY) 2024-12-31 $26.0M -$15.6M -$23.6M -$24.4M $101.3M β€”
FY2023 (FY) 2023-12-31 $193.4M -$62.1M -$47.7M -$47.7M β€” β€”

3. CNTB Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

βœ“ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is CNTB stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

As of 2026-11-03, Connect Biopharma Holdings Limited (NASDAQ: CNTB) is rated E (Strong Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 26/100 at a spot price of $0.78 (-3.13% 1D, market cap $50.5M). Pillar breakdown: Fundamental Cash Engine 7/20, Institutional 13F & Options Flow 3/20, SEC Balance-Sheet Forensics 5/20, FRED Macro Regime Fit 8/20, and Executive Insider Alignment 3/20. Across 1015 tracked Health Care issuers, CNTB ranks #913 in composite RQD confidence.

How does CNTB compare to HYPD and CTOR in the Health Care sector?

Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), CNTB carries a Roarable E (26/100 RQD), trailing P/E of N/A, gross margin of β€”, and ROIC of -35.0%. By comparison, HYPD (Hyperion DeFi Inc.) holds a D- grade (38/100 RQD, P/E N/A, ROIC -35.0%, cap $49.7M) and CTOR (Citius Oncology Inc.) posts a E grade (34/100 RQD, P/E N/A, ROIC -35.0%, cap $51.5M). Among the 5-stock peer group, CNTB leads on earnings multiple (N/A) while CNTB leads on capital efficiency (-35.0% ROIC).

What are the biggest fundamental strengths and SEC risk factors for CNTB?

Per CNTB's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001835268), Connect Biopharma Holdings Limited generated $64.0K in revenue (-99.8% YoY), -$55.5M in net income, and -$51.6M in free cash flow against $56.1M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately. Institutional options positioning shows a 50% call / 50% put premium split.

Where is CNTB trading relative to its 50-day, 200-day, and 52-week technical levels?

CNTB last traded at $0.78 (-3.13% on volume of 523,405 shares), positioning the stock -41.35% below its 50-day simple moving average ($1.33) and -64.38% below its 200-day simple moving average ($2.19). Across its 52-week range of $0.73 to $3.82, CNTB sits at the 1.6% percentile with a 14-day RSI of 33.2 (NEUTRAL RANGE) and an implied next-earnings move of Β±12.5% ($1.00 to $0.88).

Direct Sub-Reports: CNTB RQD Cockpit CNTB 12M Forecast CNTB Earnings & Move CNTB Dividends & DRIP CNTB Insiders & 13F CNTB Whale Options CNTB Profit Sankey CNTB News & Why
ROARABLE RATING BRIEF β€’ RQD 26/100 (E) βœ“ SEC XBRL & RQD VERIFIED

CNTB β€” Connect Biopharma Holdings Limited: What the Facts Mean to a Prospective Investor

Methodology: RQD v6.2 Deterministic 5-Pillar & SEC XBRL Audit
Updated: 2025-12-31

1. Roarable Rating Brief: What This Means to a Prospective Investor

Connect Biopharma Holdings Limited (CNTB) earns a live Roarable RQD composite score of 26/100, corresponding to a E letter grade (Roarable Strong Sell) at a spot price of $0.78 (-3.13% 1D, market capitalization $50.5M).

  • Fundamental Cash Engine (7/20): Anchored by return on invested capital (ROIC) of -35.0%, gross margin of β€”, operating margin of -60.0%, and free cash flow yield of β€”.
  • Whale 13F & Options Flow (3/20) + Insider Conviction (3/20): Tracks institutional 13F accumulation, CBOE options call/put positioning, and SEC Form 4 / Congressional PTR filings.
  • Macro Regime Fit (8/20) + Forensic Balance Sheet (5/20): Incorporates a 1.00x equity beta, Altman Z-Score of N/A, Piotroski F-Score of 2/9, and Debt/Equity of N/A.

2. Business Model, Unit Margins & SEC Financial Trajectory

Connect Biopharma Holdings Limited (CNTB) is a NASDAQ-listed issuer in the Health Care sector, within the Biotechnology: Pharmaceutical Preparations industry. The issuer's market capitalization is $0.1B.

In its latest audited SEC EDGAR 10-K filing for FY2025 (filed 2025-12-31), Connect Biopharma Holdings Limited (CNTB) reported $64.0K in annual revenue (up from $26.0M in FY2024, -99.8% YoY) and -$55.5M in GAAP net income. Over the multi-year SEC filing window from FY2023 ($193.4M revenue, -$62.1M net income) through FY2025, CNTB scaled operating cash flow to -$51.2M and free cash flow to -$51.6M, backed by $56.1M in total assets against $0 in total debt.

3. Institutional Bull vs. Bear Thesis & Valuation Tradeoff

  • πŸ‚ Primary Bull Case (E β€’ RQD 26/100): Established market leader in Health Care with deep daily trading liquidity. Free cash flow yield of β€” and institutional whale pillar of 3/20. With Fundamental Cash Engine at 7/20 and Institutional Whale Flow at 3/20, sustained execution supports upside toward the upper end of the $0.73 – $3.82 52-week range.
  • 🐻 Primary Bear Case & Valuation Risk: Company executives have done more routine share selling than personal cash buying lately. Investors must weigh current valuation against -60.0% operating margins and a 1.00x macro beta.

4. 2nd-Order Butterfly Ripples & Key Questions to Watch

Operating in Biotechnology: Pharmaceutical Preparations (Health Care), CNTB carries a macro regime beta of 1.00 and gross margin of β€”.

  • Key Question #1: Can CNTB sustain or expand its -60.0% operating margin and -35.0% ROIC against Biotechnology: Pharmaceutical Preparations peers over the next 4 quarters?
  • Key Question #2: Following FY2025 revenue of $64.0K and free cash flow of -$51.6M, how will capital allocation balance growth reinvestment against $0 in total debt?
  • Key Question #3: How sensitive is CNTB's equity valuation to Health Care capital spending cycles and macro interest-rate shifts (Beta 1.00x)?

CNTB Live News Feed, Press Releases & Catalyst Wire

Real-time company headlines, analyst actions, and sector developments for Connect Biopharma Holdings Limited (CNTB) β€’ Click "Debate This Headline" to argue it in the Roar Pit below

πŸ’¬ Jump to CNTB Debate Forum (3) ↓
πŸ”΄ RISK WATCH Yahoo Finance β€’ 34d ago
Connect Biopharma Announces Positive Preliminary Topline Data from its Global Phase 2 Study of Rademikibart as an Add-on Treatment for Acute Exacerbations in Adults with COPD and Type 2 Inflammation

– Rademikibart significantly reduced the rate of treatment failure compared to placebo through one month by 81% (p=0.0122) – – Rademikibart significantly reduced the rate of new moderate to severe COPD exacerbations thro

Read Full Source β†—
πŸ”₯ THE ROAR PIT β€’ LIVE COMMUNITY DEBATE 3 Active Posts & Replies

CNTB Bull vs. Bear Conversation Board β€” What's Your Call at $0.78?

πŸ‚ 67% BULLISH CONVICTION COMMUNITY TUG-OF-WAR ON CNTB 🐻 33% BEARISH CONVICTION
1. Pick Your Side on CNTB:
πŸ’‘ Tip: Back up your call with a price target or RQD metric to get upvoted to the top.
AL AlphaFlow_Cap RQD DEBATE OPENER β€’ Verified $100K Arena Trader πŸ‚ BULLISH 🎯 Target: $1.03 (+28.7%)
πŸ“Œ Pinned Debate

Institutional accumulation and options positioning score 12 / 20, the strongest RQD pillar, while debt-to-equity of 0.5 indicates moder

The street is overcomplicating Connect Biopharma Holdings Limited (CNTB). Institutional accumulation and options positioning score 12 / 20, the strongest RQD pillar, while debt-to-equity of 0.5 indicates moderate leverage.. With an RQD score of 26/100 (E) and Forensic Balance Sheet at 5/20, any positive earnings surprise or guidance raise forces underweight funds to chase above $0.86.

SectorRotator πŸ‚ BULL

@ShortSeller_Dan Fair point on current EV/EBITDA multiples, but you're ignoring the forward operating leverage in Biotechnology: Pharmaceutical Preparations. If gross margin (0.0%) holds, EPS grows into the multiple faster than bears think.

SH ShortSeller_Dan RQD DEBATE OPENER β€’ Forensic Short Bias 🐻 BEARISH 🎯 Target: $0.65 (-18.8%)
Spot @ $0.80

FY 2025 operating loss of -$58.1M exceeds $0.1M revenue, with ROIC at -35%, FCF yield at 0%, and cash falling from $78.2M to $38.3M.

I respect the product at Connect Biopharma Holdings Limited, but the stock at $0.80 is a different story. FY 2025 operating loss of -$58.1M exceeds $0.1M revenue, with ROIC at -35%, FCF yield at 0%, and cash falling from $78.2M to $38.3M.. FCF yield is 0.0% and RQD sits at 26/100 (E) β€” why pay up here when you can wait for next quarter's numbers?

LIVE TAPE